-
Metabolic Readouts of Sorafenib Resistance
2026-08-16
How HNF4A-AS1, lipid remodeling, and ferroptosis research can be translated into a disciplined metabolic phenotyping workflow using fluorescence-based glucose uptake measurements.
-
TGEV M–HSC70 Interaction Drives Viral Internalization
2026-08-15
Ji et al. identify HSC70 as a host factor that connects the TGEV membrane protein with clathrin-mediated endocytosis during early infection. The study expands the role of coronavirus M protein beyond assembly and budding, while highlighting HSC70 ATPase activity and M–HSC70 binding as mechanistic points for further investigation.
-
BIBR 1532: Telomerase Assay Guide
2026-08-14
A scenario-based guide to using BIBR 1532 for telomerase activity assays, cancer cell proliferation inhibition, and apoptosis interpretation. It explains solvent compatibility, protocol controls, literature boundaries, and vendor-selection considerations for SKU A1945.
-
DAPI Solution (1 mg/mL): Reliable Cell Assays
2026-08-14
Learn how DAPI and DAPI Solution (1 mg/mL), SKU K2401, can strengthen nuclear visualization, membrane-compromise measurements, and flow cytometry DNA staining in cell-based assays. This scenario-driven guide separates validated product specifications from workflow recommendations and explains how to interpret DAPI data alongside mechanistic cancer research.
-
ω-Agatoxin IVA TFA: An Assay-Logic Guide
2026-08-13
ω-Agatoxin IVA TFA is more than a P/Q-type channel blocker: it is a precision tool for separating Cav2.1-dependent current, neurotransmitter release, and downstream neuroprotection. This guide translates its P-versus-Q pharmacology into practical neuronal calcium current recording, synaptic transmission research, and epilepsy study decisions.
-
Asunaprevir: From Protease Mechanism to Translation
2026-08-13
Asunaprevir (BMS-650032) illustrates how a highly selective HCV NS3/4A protease inhibitor can be evaluated as more than an enzyme assay hit. This thought-leadership analysis connects molecular mechanism, genotype-aware validation, hepatotropic exposure, translational modeling, and lessons from chromatin-focused drug discovery.
-
Lisinopril dihydrate: Assay Logic in RAS Models
2026-08-12
Lisinopril dihydrate is a long-acting ACE inhibitor for mechanistic renin–angiotensin system research. This guide connects biochemical potency, aminopeptidase selectivity, formulation control, and cardiovascular or renal disease models.
-
Pravastatin sodium Research Workflows
2026-08-12
Pravastatin sodium enables mechanism-led cholesterol biosynthesis inhibition, LDL handling studies, and transporter-aware hepatocyte workflows. This practical guide connects dose selection, cytotoxicity controls, macrophage assays, and botanical interaction testing for more interpretable results.
-
Ziprasidone Augmentation in Anxious Depression
2026-08-11
This post-hoc analysis examined whether anxious depression moderated the effects of ziprasidone augmentation added to escitalopram in an 8-week randomized, double-blind trial. Ziprasidone augmentation produced comparable depressive symptom improvement in patients with and without anxious depression, while its apparent benefit for anxiety symptoms in the more anxious subgroup was not clinically significant.
-
JNJ-26854165: From p53 Biology to Translation
2026-08-11
A translational framework for using JNJ-26854165 (Serdemetan) to connect HDM2-p53 biology with rigorous measurements of growth inhibition, apoptosis, migration, and radiation response.
-
SIS3 for Smad3 Mechanism Studies
2026-08-10
SIS3 is a selective Smad3 inhibitor for separating canonical TGF-β signaling from Smad2-associated responses in fibrosis, renal, and oncology assays. This practical guide translates pathway biology into controlled workflows, branch-specific readouts, and troubleshooting strategies for preclinical research.
-
MIR9 Methylation Activates FGFR1 and CDK6 in ALL
2026-08-09
The reference study links MIR9-family promoter hypermethylation with reduced MIR9 expression, increased FGFR1 and CDK6 activity, and adverse outcomes in acute lymphoblastic leukaemia. Its functional inhibitor experiments provide a rationale for studying FGFR1 and CDK6-RB signaling as therapeutic vulnerabilities, while also illustrating the limits of inferring pathway causality from pharmacological perturbation alone.
-
Hexose Diphosphate for Reliable Cell Assays
2026-08-08
Learn how hexose diphosphate, SKU M1436, can support reproducible metabolic, viability, proliferation, and inflammation-related assays. This scenario-based guide covers solvent compatibility, protocol design, interpretation, and practical vendor-selection criteria.
-
Ashwagandha Digestive Metabolomics by LC–MS/MS
2026-08-07
This 2026 study combines simulated gastrointestinal digestion with LC–MS/MS, untargeted metabolomics, and molecular networking to track how Withania somnifera extracts and key withanolides change before absorption. Its main practical contribution is showing that digestive stability is compound- and plant-part dependent, supporting more realistic preclinical models for botanical pharmacokinetics.
-
Cardamomin Attenuates Oxidative Damage in Ischemic Stroke Mo
2026-08-07
This study elucidates the neuroprotective and antioxidant actions of cardamomin, a chalcone extracted from Amomum villosum, in both in vitro and in vivo models of oxidative stress and cerebral ischemic stroke. The research provides mechanistic insight into NRF2 pathway activation and cell death regulation, with practical implications for tissue viability assessment in stroke research.